Identifying therapeutic targets in gastric cancer: The current status and future direction

Beiqin Yu, Jingwu Xie

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalActa Biochimica et Biophysica Sinica
Volume48
Issue number1
DOIs
StatePublished - May 27 2015

Fingerprint

Stomach Neoplasms
Emitter coupled logic circuits
Pharmaceutical Preparations
Tumors
Neoplasms
Therapeutics
Gastrointestinal Agents
Gastrointestinal Stromal Tumors
Drug Resistance
Direction compound
Clinical Trials
Imatinib Mesylate

Keywords

  • cancer stem cell
  • gastric cancer
  • targeted therapy
  • Wnt, hedgehog

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Identifying therapeutic targets in gastric cancer : The current status and future direction. / Yu, Beiqin; Xie, Jingwu.

In: Acta Biochimica et Biophysica Sinica, Vol. 48, No. 1, 27.05.2015, p. 90-96.

Research output: Contribution to journalArticle

@article{c80fe3efdbd248d7b26c4fc207400f6b,
title = "Identifying therapeutic targets in gastric cancer: The current status and future direction",
abstract = "Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.",
keywords = "cancer stem cell, gastric cancer, targeted therapy, Wnt, hedgehog",
author = "Beiqin Yu and Jingwu Xie",
year = "2015",
month = "5",
day = "27",
doi = "10.1093/abbs/gmv084",
language = "English (US)",
volume = "48",
pages = "90--96",
journal = "Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica",
issn = "1672-9145",
publisher = "Shanghai Kexue Jishu Chubanshe/Shanghai Scientific & Technical Publishers",
number = "1",

}

TY - JOUR

T1 - Identifying therapeutic targets in gastric cancer

T2 - The current status and future direction

AU - Yu, Beiqin

AU - Xie, Jingwu

PY - 2015/5/27

Y1 - 2015/5/27

N2 - Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.

AB - Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.

KW - cancer stem cell

KW - gastric cancer

KW - targeted therapy

KW - Wnt, hedgehog

UR - http://www.scopus.com/inward/record.url?scp=84960376949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960376949&partnerID=8YFLogxK

U2 - 10.1093/abbs/gmv084

DO - 10.1093/abbs/gmv084

M3 - Article

C2 - 26373844

AN - SCOPUS:84960376949

VL - 48

SP - 90

EP - 96

JO - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

JF - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

SN - 1672-9145

IS - 1

ER -